GILD Gilead Sciences Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 31.62 P/E
- 8.66 P/S
- 8.48 P/B
- 1.786 EPS
- 50.50% Cash ROIC
- 3.94 Cash Ratio
- 0 / 0% Dividend
- 10.83M Avg. Vol.
- 790.12M Shares
- 86.137B Market Cap.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
4-traders (press release) - 11 hours ago
EMA Validates Gilead's Marketing Application For Sofosbuvir - RTTNews - RTT News
SBWire (press release) - 20 hours ago
Gilead Sciences Stock Rating Reaffirmed by JPMorgan Chase (GILD) - Mideast Time
4-traders (press release) - May 17, 2013
4-traders (press release) - May 15, 2013
Schaeffers Research - May 14, 2013
NASDAQ - May 20, 2013
MarketWatch (press release) - May 14, 2013
SBWire (press release) - May 13, 2013
RTT News - May 3, 2013
Gilead combo hepatitis C pill effective in small trial - Reuters
4-traders (press release) - Apr 25, 2013
Stocks In News (HomeAway, Synergy Pharmaceuticals Inc, IAMGOLD ... - Mesh Press (press release)